MicroPharm is a fully integrated developer and manufacturer of polyclonal therapeutics, targeting infectious disease and acute toxic events. MicroPharm's core expertise lies in the raising of antisera containing high levels of specific antibodies directed against toxic molecules or viral targets and the subsequent purification and modification of such antibodies to produce a range of immunotherapeutic products for clinical use. All are designed to treat acute, life-threatening emergencies, have been developed at the request of the medical profession and are required urgently either because no alternative exists or because any alternative is ineffective and/or unsafe. MicroPharm also provides a contract development, manufacturing and filling service to third parties.

Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom.

Leveraging the extensive knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

Santalis Pharmaceuticals, Inc. is a private company headquartered in San Antonio, TX, that manufactures and markets botanical pharmaceuticals. On August 04, 2015 A.C.N. 092 200 854 Ltd. acquired Santalis Pharmaceuticals, Inc. for $95 million.\nThe company says this about itself: Santalis Pharmaceuticals, Inc. is a wholly owned subsidiary of Quintis, Ltd. (ASX: QIN). Santalis, and its sister company, Santalis Healthcare Corporation (formerly known as ViroXis Corporation), were acquired by Quintis in July 2015 and are developing scientifically- and clinically-validated over-the-counter and prescription products that utilize Quintis’ cultivated, sustainable, pharmaceutical­grade Sandalwood Album Oil (SAO). Santalis’ product development programs are focused in dermatology and oral health, where SAO’s well documented safety and anti-infective, anti­proliferative and anti-inflammatory properties are well suited to a number of prevalent and under­served conditions.

Sanofi Pasteur Biologics LLC, part of Sanofi, is a company headquartered in Cambridge, MA, that engages in the research, production and distribution of pharmaceutical products.

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed in both oral tablet and intravenous formulations for use as a first-line monotherapy antibiotic for ABSSSI, CABP, urinary tract infections (UTI) and other serious community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has received Qualified Infectious Disease Product (QIDP) designation by the U.S. Food and Drug Administration for both the oral and intravenous formulations in all three of these infectious disease categories. Paratek has Special Protocol Assessment agreements with the FDA for the phase 3 trials planned in ABSSSI and CABP.

Summit Co., Ltd. is a company headquartered in the South Korea that manufactures electrical measuring, testing and analysis instruments. It was founded in 2007.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

ActivBiotics develops and sells antibiotics and combination therapies for the treatment of acute and chronic infections. The company’s lead product candidate, Rifalazil, is a proprietary, orally administered antibacterial agent which is in a Phase III clinical trial for the treatment of intermittent claudication associated with peripheral arterial disease. The company’s other product candidate, M40403, is a proprietary small molecule to mimic the function of a naturally occurring enzyme, which plays a role in various inflammatory disease states. It also develops ABI-0043 as a proprietary antibacterial agent for the treatment of complicated skin and skin structure infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus. In addition, the company identifies product candidates from its proprietary compound libraries for the treatment of inflammatory diseases and bacterial infections. The company’s superoxide dismutases (SOD) mimetic library consists of approximately 250 small molecules that mimic naturally occurring SOD enzymes.

NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom.

CNJ Holdings Inc., a subsidiary of Emergent BioSolutions, Inc., is a Canadian company. The firm functions as an investment holding company.

Kamtek, Inc. is a private company headquartered in the United States. The firm engages in aluminium die casting.

Arizona Board of Regents oversees college activities. The company was founded in 1864 and is headquartered in Phoenix, AZ.

Nanjing Bidike Pharmaceutical Technology Co., Ltd., established on 2011-12-12, Business scope includes pharmaceuticals,R & D and technical services of health products,Consulting and Transfer.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Zhu Hai Tai Nuo Mai Bo Zhi Yao Gu Fen You Xian Gong Si, established on 2015-12-17, Business scope includes general items:Medical Research and Experimental Development(remove human stem cells,Development and application of genetic diagnosis and treatment technology);Natural science research and experimental development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Drug Wholesale;Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.